Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 14/20 | 0.69 |
| ▸ | EZH1 | Q92800 | 10/20 | 0.54 |
| ▸ | EED | O75530 | 4/20 | 0.54 |
| ▸ | RBBP4 | Q09028 | 4/20 | 0.54 |
| ▸ | SUZ12 | Q15022 | 4/20 | 0.54 |
| ▸ | AEBP2 | Q6ZN18 | 4/20 | 0.54 |
| ▸ | RBBP7 | Q16576 | 3/20 | 0.54 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.54 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23863673 | 0.95 | EZH2 (0.61) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734369 | 0.84 | EZH1 (0.55) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734375 | 0.83 | EZH2 (0.82) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734368 | 0.82 | EZH2 (0.73) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL29408698 | 0.81 | EZH2 (1.00) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734431 | 0.81 | EZH2 (1.00) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL17734376 | 0.81 | EZH2 (0.80) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL23863676 | 0.79 | EZH1 (0.50) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL10255922 | 0.78 | EZH2 (0.88) | EZH2EZH1EEDRBBP4SUZ12 | |
| SCHEMBL23863645 | 0.78 | EZH2 (0.65) | EZH2EZH1EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-3885343-A1 | INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| WO-2016073956-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073903-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | EZH2 3/4885EZH1 31/4885EED 58/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | EZH2 1/4885EZH1 2/4885EED 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.